Patent · US Active

Use of VEGFR1 as a biomarker

US9133515B2 · kind B2 · utility

0Cited by

4References

4Claims

0Family size

Assignee

Sapience Therapeutics, Inc. · DE

Inventors

Klaus Giese · Berlin, DE
Joerg Kaufmann · Isenbüttel, DE

Key dates

Filing date	May 15, 2013
Grant date	Sep 15, 2015
Priority date	—
Expiry date	May 15, 2033

Classification

Technology area (CPC G)Physics
CPC primaryG01N2800/52
WIPO fieldMeasurement
WIPO sectorInstruments

Abstract

The present invention is related to the use of VEGFR1 or of a nucleic acid coding for VEGFR1 as a biomarker in a method for the treatment of a subject, wherein the method for the treatment comprises administering to the subject a PKN3 inhibitor.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.